Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study
![Creative Medical Technology Holdings](https://nationalstemcelltherapy.com/wp-content/uploads/2022/04/Creative_Medical_Technology_Holdings_Inc_Logo.jpg)
PHOENIX, July 28, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the Company’s OvaStem® pilot study. The data shows significant efficacy of […]